Patients How prioritising sustainability efforts yields long-term gro... The pharmaceutical industry is at a pivotal juncture.
R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
